Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticoid osteoporosis

I R Reid1, A G Veale, J T France

  • 1Department of Medicine, University of Auckland, New Zealand.

The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?

Expert opinion on drug safety·2022
Same author

Bone-friendly lifestyle and the role of calcium or vitamin D supplementation.

Climacteric : the journal of the International Menopause Society·2021
Same author

Publisher Correction to: Development of the Asia Pacific Consortium on Osteoporosis (APCO) framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Management of Paget's disease of bone.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.

Journal of internal medicine·2019

Glucocorticoids can cause osteoporosis by inhibiting bone formation and reducing testosterone. Bone density loss is significant, especially in trabecular bone, requiring monitoring and interventions like calcium, hormone replacement, or medications.

Area of Science:

  • Endocrinology
  • Metabolic Bone Disease

Background:

  • Glucocorticoids significantly impact calcium metabolism, leading to osteoporosis.
  • A primary mechanism involves the inhibition of bone formation.
  • In men, reduced testosterone levels contribute to glucocorticoid-induced bone loss.

Purpose of the Study:

  • To outline the effects of glucocorticoids on calcium metabolism and bone health.
  • To discuss the clinical management of glucocorticoid-induced osteoporosis.
  • To highlight the role of bone densitometry and therapeutic interventions.

Main Methods:

  • Review of the literature on glucocorticoid effects on bone metabolism.
  • Analysis of factors influencing bone density reduction.
  • Discussion of diagnostic and therapeutic strategies for managing osteoporosis.

Related Experiment Videos

Main Results:

  • Glucocorticoid treatment reduces bone density by 10-20% at assessed sites, with greater deficits in trabecular bone.
  • Dose and duration of steroid therapy correlate with osteopenia severity.
  • Biochemical markers of calcium metabolism are not reliable predictors of bone loss.

Conclusions:

  • Bone densitometry is crucial for managing patients on steroid therapy.
  • Optimizing calcium intake and hormone replacement are initial management steps.
  • Bisphosphonates, calcitonin, fluoride, or vitamin D metabolites may be added for severe bone loss, with thiazide diuretics as an adjunct therapy.